• 1.

    Mustafa R, et al. Clinical trials in nephrology: An updated systematic review of ClinicalTrials.gov. Kidney Week 2019; FR-PO1199. https://www.asn-online.org/education/kidneyweek/2019/program-abstract.aspx?controlId=3237149

    • Search Google Scholar
    • Export Citation
  • 2.

    Levin A, et al. Global kidney health 2017 and beyond: A roadmap for closing gaps in care, research, and policy. Lancet 2017; 390:18881917. doi: 10.1016/S0140-6736(17)30788-2

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 3.

    Evangelidis N, et al. Developing a set of core outcomes for trials in hemodialysis: An international Delphi survey. Am J Kidney Dis 2017; 70:464475. doi: 10.1053/j.ajkd.2016.11.029

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 4.

    Flythe JE, et al. Cultivating a research-ready dialysis community. J Am Soc Nephrol 2019; 30:375380. doi: 10.1681/ASN.2018101059

  • 5.

    Thompson A, et al. Complete and partial remission as surrogate end points in membranous nephropathy. J Am Soc Nephrol 2015; 26:29302937. doi: 10.1681/ASN.2015010091

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 6.

    Allon M, et al. Recommended clinical trial end points for dialysis catheters. Clin J Am Soc Nephrol 2018; 13:495500. doi: 10.2215/CJN.12011116

  • 7.

    Smith KA, et al. Addressing the need for clinical trial end points in autosomal dominant polycystic kidney disease: A report from the Polycystic Kidney Disease Outcomes Consortium (PKDOC). Am J Kidney Dis 2019; 73:533541. doi: 10.1053/j.ajkd.2018.11.001

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 8.

    Levey AS, et al. Change in albuminuria and GFR as end points for clinical trials in early stages of CKD: A scientific workshop sponsored by the National Kidney Foundation in collaboration with the US Food and Drug Administration and European Medicines Agency. Am J Kidney Dis 2020; 75:84104. doi: 10.1053/j.ajkd.2019.06.009

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 9.

    Levey AS, et al. GFR decline as an end point for clinical trials in CKD: A scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration. Am J Kidney Dis 2014; 64:P821P835. doi: 10.1053/j.ajkd.2014.07.030

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 10.

    Beathard GA, et al. Definitions and end points for interventional studies for arteriovenous dialysis access. Clin J Am Soc Nephrol 2018; 13:501512. doi: 10.2215/CJN.11531116

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 11.

    Mackay M, et al. Establishing surrogate kidney end points for lupus nephritis clinical trials: Development and validation of a novel approach to predict future kidney outcomes. Arthritis Rheumatol 2019; 71:411419. doi: 10.1002/art.40724

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 12.

    Thompson A, et al. Proteinuria reduction as a surrogate end point in trials of IgA nephropathy. Clin J Am Soc Nephrol 2019; 14:469481. doi: 10.2215/CJN.08600718

    • Crossref
    • Search Google Scholar
    • Export Citation

Patients as Partners in Clinical Trial Development—What Are We Waiting For?

  • 1 Barbara S. Gillespie, MD, FASN, is vice president, Therapeutic Head of Nephrology, Covance, and adjunct professor, Division of Nephrology and Hypertension, University of North Carolina.
Restricted access
Save